Enveda

Overview

Enveda is a privately held AI biotechnology startup based in Boulder, Colorado, that discovers medicines from the chemistry of living organisms (Wall Street Journal). Its core technology is PRISM, an AI foundation model trained on the chemistry of living organisms that identifies naturally occurring molecules in plants, microbes, and the human body, predicts their structures, and ranks them for therapeutic potential (Boston Life Sciences Times). Since its 2019 founding the platform has generated 17 drug development candidates, three of which are in human clinical trials (Boston Life Sciences Times). In September 2026 the company closed a $311 million Series E financing led by Catalio Capital Management, doubling its valuation to about $2 billion and taking its total capital raised past $845 million (Wall Street Journal).

From ethnobotany to a foundation model

Enveda’s founder, Viswa Colluru, was an early employee of Recursion Pharmaceuticals, the AI drug-discovery company that went public in 2021, and left Recursion in 2019 to start Enveda in Boulder (TechCrunch). His founding observation was anthropological as much as chemical: geographically separated cultures that never communicated were much more likely to use similar plants for similar diseases and symptoms — “literally thousands of years of experiential human wisdom” about which plants help stomach aches, fevers, or headaches (TechCrunch).

Enveda digitized that wisdom into a database of 38,000 medicinal plants linked to about 12,000 diseases and symptoms (TechCrunch). Unlike traditional approaches that study individual molecules one at a time, Enveda’s transformer model deciphers the “chemical language” of an entire sample at once, predicting molecular shapes so scientists can prioritize the sets of molecules most likely to become medicines (TechCrunch). The Wall Street Journal describes the same system as identifying and ranking therapeutic compounds found in plants and microbes, predicting their structures and biological functions to generate new treatments (Wall Street Journal).

The company says its platform can identify commercially viable molecules roughly four times faster and at one-tenth the cost of traditional methods (Wall Street Journal). Colluru’s framing is that the pharmaceutical industry has become excellent at commercializing a molecule once it is known to be right but “increasingly worse at finding the right molecule” — and that AI should “lead the way for answers that already exist in nature” (Wall Street Journal). Notably, while much attention in natural-product drug discovery has gone to cannabis and psychedelics, Enveda deliberately does not study their compounds, on the grounds that they are “just a tiny fraction of the natural world” (TechCrunch).

The annual funding cycle

Enveda has settled into an unusually regular financing rhythm — roughly one large round per year (Fierce Biotech). In June 2024 it raised a $55 million Series B2 from new investors including Microsoft, The Nature Conservancy, Premji Invest, and Lingotto Investment Fund, alongside existing backers Kinnevik, True Ventures, FPV, Level Ventures, and Jazz Venture Partners, bringing total capital to $230 million (TechCrunch). Microsoft also provided cloud credits as part of the deal, separate from its cash investment (TechCrunch).

Five months later Enveda closed a $130 million Series C to fund a Phase 1 trial of its eczema candidate ENV-294; Sanofi added to the round in February 2025, bringing the Series C total to $150 million (Fierce Biotech). In September 2025 came a second $150 million round, the Series D led by Premji Invest with support from Baillie Gifford, Kinnevik, Lingotto, Peakline Partners, FPV, Socium Ventures, Dimension, Level Ventures, Henry Kravis, IA Ventures, and Lux Capital, pushing total funding beyond $500 million (Fierce Biotech). Alongside the Series D, Enveda appointed Mikael Dolsten — Pfizer’s former chief scientific officer, credited with moving more than 150 drug candidates into clinical trials — to its board (Fierce Biotech).

The September 2026 Series E was the largest yet: $311 million led by Catalio Capital Management, with new investors Durable Capital Partners, ICONIQ, Lightspeed, Surveyor Capital, accounts advised by T. Rowe Price Investment Management, Digitalis Ventures, a sovereign wealth fund, and Alderline Group, plus existing investors Baillie Gifford, Premji Invest, FPV Ventures, True Ventures, Kinnevik, Dimension, Lifeforce Capital, and Lux Capital (Boston Life Sciences Times). Catalio co-founder and managing partner George Petrocheilos joined Enveda’s board in connection with the round (Boston Life Sciences Times). Colluru used the announcement to set a strikingly ambitious goal: for Enveda to become a household name and deliver medicines affecting hundreds of millions of people within a decade, building a business capable of carrying medicines “from discovery through late-stage development, and do it faster and at lower cost than the industry has come to accept” (Fierce Biotech).

The clinical pipeline

Three PRISM-derived candidates are in human trials (Boston Life Sciences Times). The lead program, ENV-294, is an oral small molecule for atopic dermatitis (eczema) and asthma (Fierce Biotech). Enveda posted Phase 1b data in July 2026 linking it to a mean 68% reduction in eczema area and severity by Day 28, deepening to 85% by Day 42, and is running Phase 2a trials in atopic dermatitis and asthma (Fierce Biotech). The company pitches ENV-294 as an asset that could pair the efficacy of JAK inhibitors with the safety profile of drugs targeting IL-4 and IL-13, though its precise mechanism of action remains undisclosed (Fierce Biotech).

ENV-308 is the company’s metabolic candidate: a first-in-class oral small molecule engineered to replicate the effects of the post-exertion hormone N-lactoyl-phenylalanine while being suitable for daily oral dosing (Fierce Biotech). Enveda found it by decoding the chemistry the body releases during intense physical activity, identifying a hormone that naturally suppresses appetite, and is testing whether it can help people maintain weight loss after stopping GLP-1 medicines (Wall Street Journal). A third candidate, ENV-6946, is in Phase 1 development for inflammatory bowel disease as a gut-preferred inhibitor of the NLRP3/TL1A+ pathway (Fierce Biotech), described as an oral treatment targeting multiple inflammatory pathways (Boston Life Sciences Times). Two further candidates were at the IND-enabling stage as of late 2025 (Fierce Biotech). The company has also been expanding its leadership, hiring Novo Nordisk’s former head of disease prevention over the past year (Wall Street Journal).

What this profile does not claim

This profile does not claim that ENV-294, ENV-308, or ENV-6946 are effective or will reach the market — the clinical data described is early-stage and was announced by the company, not independently verified. It does not state ENV-294’s mechanism of action, which Enveda had not disclosed as of late 2025. It does not claim the company’s “four times faster, one-tenth the cost” efficiency figure has been independently validated — it is the company’s own claim as reported by the Wall Street Journal. The $2 billion valuation and $845M+ total raised are figures from the September 2026 Series E announcement. This profile makes no claim about Enveda’s current headcount, revenue, or profitability, none of which were verified from fully-read independent sources.